Rim S. Kim

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer”.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

npj Breast Cancer(2020)10.1038/s41523-020-0156-0

N/A

0DataRank · unranked

208 citations

Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen +95 more

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

npj Breast Cancer(2020)10.1038/s41523-020-0154-2

N/A

0DataRank · unranked

168 citations

Elisabeth Specht Stovgaard, Eva Balslev, Jeppe Thagaard, Weijie Chen, Sarah Dudgeon +95 more

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

npj Breast Cancer(2021)10.1038/s41523-021-00346-1

N/A

0DataRank · unranked

280 citations

Harry R. Haynes, Elizabeth F. Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner +73 more

Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3516

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Nan Song, Rim S. Kim, Greg Yothers +12 more

Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3607

N/A

0DataRank · unranked

1 citations

Lujia Chen, Ying Wang, Chunhui Cai, Rim S. Kim, Corey Lipchik +12 more

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.140

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Rim S. Kim, Patrick G. Gavin, Debora Fumagalli +13 more